Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03867539 · ClinicalTrials.gov registry record · Phase 4

Exparel and Education to Avoid Opioids After Carpal Tunnel Release

A Phase 4 study of Carpal Tunnel Syndrome, sponsored by Kettering Health Network.

Recruiting
Registry status
Phase 4
Development phase
64
Enrollment target
2
Study locations

NCT03867539 is a Phase 4 study of Carpal Tunnel Syndrome that is actively recruiting participants, run by Kettering Health Network. The registered enrollment target is 64 participants, below the 220-participant average among 21 other Carpal Tunnel Syndrome trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03867539, a Phase 4 study of Carpal Tunnel Syndrome, is actively recruiting participants, sponsored by Kettering Health Network.

RECRUITING
Registry status
Phase 4
Development phase
64 participants
Enrollment target
2
Study locations

Study Summary

This trial seeks to use the long acting local anesthetic Exparel, in conjunction with opioid education, to attempt to avoid any post-operative opioid use following carpal tunnel surgery. This group will be compared with a "standard" group that receives non-liposomal bupivacaine, opioid education, and opioids.

Conditions Studied

Interventions

  • OTHER Differing pain management strategy

Study Locations (2)

Ohio

  • Orthopedic Associates of Southwest Ohio - Dayton
  • Orthopedic Associates of Southwest Ohio - Dayton

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2019-02-15
Est. Completion 2025-03-31
Phase Phase 4

Sponsor

Kettering Health Network

14 total trials

What the Registry Record Tells You About NCT03867539

The ClinicalTrials.gov registry entry for NCT03867539 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 220-participant average among 21 other Carpal Tunnel Syndrome trials with a reported enrollment target (71% lower). The listed sponsor is Kettering Health Network, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carpal Tunnel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Differing pain management strategy is the first listed.

NCT03867539 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03867539 about?

NCT03867539 is a clinical study titled "Exparel and Education to Avoid Opioids After Carpal Tunnel Release". This trial seeks to use the long acting local anesthetic Exparel, in conjunction with opioid education, to attempt to avoid any post-operative opioid use following carpal tunnel surgery. This group will be compared with a "standard" group that receives non-liposomal bupivacaine, opioid education, an...

What is the current status of trial NCT03867539?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2019-02-15. Estimated completion is 2025-03-31.

What conditions does trial NCT03867539 study?

This clinical trial studies the following conditions: Carpal Tunnel Syndrome.

What interventions are being tested in trial NCT03867539?

The interventions under investigation include: Differing pain management strategy (OTHER).

Who is sponsoring clinical trial NCT03867539?

This trial is sponsored by Kettering Health Network, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03867539 being conducted?

This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Carpal Tunnel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.